On February 2, 2018, the Judicial Panel on Multidistrict Litigation (JPML) centralized federal lawsuits filed by individuals who have suffered heart failure after taking the diabetes drug saxagliptin (marketed as Onglyza and Kombiglyze XR) in multidistrict litigation (“MDL”) in the U.S. District Court, Eastern District of Kentucky before the Honorable Karen K. Caldwell. Saxagliptin is...
Heart Failure from Diabetes Drugs, Onglyza & Kombiglyze- WILL THE LAWSUITS BE CONSOLIDATED?
On January 25, 2018, the Judicial Panel on Multidistrict Litigation (JPML) heard arguments regarding whether to centralize federal lawsuits filed by individuals who have suffered heart failure after taking the diabetes drug saxagliptin (marketed as Onglyza and Kombiglyze XR). Saxagliptin is part of the class of dipeptidyl peptidase-4 (DPP-4) inhibitor drugs, which are used with...
Heart Failure from Diabetes Drugs, Onglyza & Kombiglyze- 1/4/18 LITIGATION UPDATE
The Judicial Panel on Multidistrict Litigation (JPML) announced that it will hear arguments on January 25, 2018 regarding whether to centralize federal lawsuits filed by individuals who have suffered heart failure after taking the diabetes drug saxagliptin (marketed as Onglyza and Kombiglyze XR). (To review the JPML’s Hearing Session Order click here.) Saxagliptin is part...